CANCER RESEARCH

TABLE OF CONTENTS

IN THE SPOTLIGHT

PRIORITY REPORT

CANCER BIOLOGY

CANCER IMMUNOLOGY

TABLE OF CONTENTS

TABLE OF CONTENTS

ABOUT THE COVER



Studies have suggested that only around 30% of esophageal adenocarcinoma patients show a pathologic complete response to neoadjuvant chemotherapy. Multidimensional profiling of esophageal adenocarcinoma prior to neoadjuvant chemotherapy treatment was used to identify mechanisms and biomarkers of response. Patient response to neoadjuvant chemotherapy correlated with active preexisting immunity. The cover image shows spatial proteomics profiling of a formalin-fixed and paraffin-embedded esophageal adenocarcinoma biopsy to evaluate tumor epithelial cells (PanCK, green), macrophages (CD68, yellow), and T cells (CD3, red); nuclei were stained with DAPI (blue). For details, see article by Arbore and colleagues on page 2873.

doi: 10.1158/0008-5472.CAN-83-17-CVR